Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson, Janssen And Changzhou Yabang-QH Pharmachem To Jointly Establish Anti-Worm Drug Base

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson, Janssen Pharmaceutica NV and Changzhou Yabang-QH Pharmachem recently began construction of their co-designed raw pharmaceutical materials base in Changzhou High-tech District. Of the total investment of about RMB 57 million, the first phase will receive a RMB 35 million capital injection. The facility, which is compliant with European and U.S. GMP, will go into production within this year. At the same time, the center will apply for Europe COS and FDA authentication with Janssen's aid. When completed, the facility will be China's largest anti-worm drug production, research and export base. Most of the expanded products will go to global high-end markets such as the U.S., Europe and Australia. (Click her for more - Chinese Language)

You may also be interested in...



Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.

New China Drug Regulation Legalizes Emergency Approval Mechanism

The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.

3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

UsernamePublicRestriction

Register

SC071266

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel